[Pro-BNP Peptide in the diagnosis and prognosis of heart failure]
Brito V, Ciapponi A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, López A, Rey-Ares L
Record ID 32015000879
Spanish
Authors' objectives:
To assess the available evidence on the efficacy, safety and coverage related aspects regarding brain natriuretic peptide use for patients with acute or chronic heart failure.
Authors' recommendations:
There is high quality evidence showing that BNP and NT pro-BNP have an adequate diagnostic and prognostic performance for HF. Moderate to low quality evidence shows a potential reduction in morbidity and mortality related to treatment adjustment based on natriuretic peptides, but further assessment is still necessary.
The clinical practice guidelines recommend BNP or NT pro-BNP use to differentiate the cause of dyspnea and to estimate prognosis in chronic and acute HF.
Coverage policies consider its use to adequately characterize dyspnea, whereas only some also include its testing to estimate prognosis and adjust treatment for acute or chronic HF.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Natriuretic Peptides
- Heart Failure
- Prognosis
- Diagnosis
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.